These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 21364592

  • 1. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
    Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Rhee J, Park YI, Kim NK.
    Br J Cancer; 2011 Mar 29; 104(7):1126-34. PubMed ID: 21364592
    [Abstract] [Full Text] [Related]

  • 2. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
    Kong SY, Lim HS, Nam BH, Kook MC, Kim YW, Ryu KW, Lee JH, Choi IJ, Lee JS, Park YI, Kim NK, Park SR.
    Pharmacogenomics; 2009 Jul 29; 10(7):1147-55. PubMed ID: 19604090
    [Abstract] [Full Text] [Related]

  • 3. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH, Park SR, Ahn Y, Ryu MH, Ryoo BY, Kong SY, Yook JH, Yoo MW, Kim BS, Kim BS, Kang YK.
    Gastric Cancer; 2017 Jan 29; 20(1):146-155. PubMed ID: 26715117
    [Abstract] [Full Text] [Related]

  • 4. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH.
    Cancer Chemother Pharmacol; 2013 Nov 29; 72(5):953-64. PubMed ID: 23982118
    [Abstract] [Full Text] [Related]

  • 5. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
    Kim MJ, Kong SY, Nam BH, Kim S, Park YI, Park SR.
    Pharmacogenet Genomics; 2018 Jan 29; 28(1):23-30. PubMed ID: 29189588
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
    Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW.
    Br J Cancer; 2011 Feb 15; 104(4):605-12. PubMed ID: 21326246
    [Abstract] [Full Text] [Related]

  • 7. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
    Fang WJ, Mou HB, Jin DZ, Zheng YL, Zhao P, Mao CY, Peng L, Huang MZ, Xu N.
    Oncol Rep; 2012 May 15; 27(5):1606-10. PubMed ID: 22322240
    [Abstract] [Full Text] [Related]

  • 8. CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.
    Yang L, Zou S, Shu C, Song Y, Sun YK, Zhang W, Zhou A, Yuan X, Yang Y, Hu S.
    Genomics Proteomics Bioinformatics; 2017 Aug 15; 15(4):255-262. PubMed ID: 28811232
    [Abstract] [Full Text] [Related]

  • 9. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
    Yamada Y, Boku N, Nishina T, Yamaguchi K, Denda T, Tsuji A, Hamamoto Y, Konishi K, Tsuji Y, Amagai K, Ohkawa S, Fujita Y, Nishisaki H, Kawai H, Takashima A, Mizusawa J, Nakamura K, Ohtsu A.
    Ann Oncol; 2013 Oct 15; 24(10):2560-2565. PubMed ID: 23884439
    [Abstract] [Full Text] [Related]

  • 10. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
    Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K.
    Br J Cancer; 2008 Feb 26; 98(4):832-9. PubMed ID: 18231104
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J.
    Cancer Chemother Pharmacol; 2013 Mar 26; 71(3):789-97. PubMed ID: 23338051
    [Abstract] [Full Text] [Related]

  • 12. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J, Li QF, Yao RY, Lü HY, Jiang J, Sun YY, Song SA, Jiang T.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul 26; 32(7):515-9. PubMed ID: 21029695
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
    Kemmochi T, Egawa T, Mihara Y, Irino T, Ito Y, Nagashima A, Makino H, Yamamuro W.
    Gan To Kagaku Ryoho; 2011 Nov 26; 38(12):2351-3. PubMed ID: 22202379
    [Abstract] [Full Text] [Related]

  • 14. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
    Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M.
    Int J Oncol; 2008 May 26; 32(5):1091-6. PubMed ID: 18425336
    [Abstract] [Full Text] [Related]

  • 15. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M.
    Lancet Oncol; 2008 Mar 26; 9(3):215-21. PubMed ID: 18282805
    [Abstract] [Full Text] [Related]

  • 16. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin.
    Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Lee JH, Kim HN, Shin MH, Kweon SS, Lee JH, Kim HJ, Chung IJ.
    Cancer Sci; 2010 May 26; 101(5):1247-54. PubMed ID: 20331623
    [Abstract] [Full Text] [Related]

  • 17. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
    Lu ZM, Luo TH, Nie MM, Fang GE, Ma LY, Xue XC, Wei G, Ke CW, Bi JW.
    Tumour Biol; 2014 Apr 26; 35(4):2941-8. PubMed ID: 24318989
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J, Luo M, Cui J, Zhou S.
    Int J Clin Exp Pathol; 2015 Apr 26; 8(11):15065-71. PubMed ID: 26823845
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
    Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.
    Clin Genitourin Cancer; 2013 Sep 26; 11(3):229-37. PubMed ID: 23684781
    [Abstract] [Full Text] [Related]

  • 20. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.
    Bao Y, Yang B, Zhao J, Shen S, Gao J.
    Int J Immunogenet; 2020 Oct 26; 47(5):443-453. PubMed ID: 32173978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.